ADX-629 ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 160 | Congenital ichthyosis | 1 |
160. Congenital ichthyosis
Clinical trials : 42 / Drugs : 71 - (DrugBank : 21) / Drug target genes : 18 - Drug target pathways : 112
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05443685 (ClinicalTrials.gov) | January 2, 2023 | 10/6/2022 | ADX-629 Therapy for Sjogren-Larsson Syndrome | An Open-Label, Phase 1/2, Single-Site Study of the Safety, Biochemical Efficacy, and Exploratory Clinical Effects of Oral ADX-629 in Subjects With Sjögren-Larsson Syndrome | Sjogren-Larsson Syndrome | Drug: ADX-629 | William Rizzo, MD | NULL | Recruiting | 18 Years | 50 Years | All | 10 | Phase 1/Phase 2 | United States |